David Cordas dos Santos

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

March, 2025

David Cordas dos Santos

Sep 14, 2024, 17:46 | Insight

Kai Rejeski: Second Primary Malignancies following CAR T-cell therapy

Kai Rejeski shared a post on X about a recent paper by Tobias Tix et…

Jul 9, 2024, 06:46 | Blog

David Cordas dos Santos: Nonrelapse mortality after CAR-T cell treatment

David Cordas dos Santos, PostDoc at Dana-Farber Cancer Institute, made the following post on X:…

Jul 8, 2024, 17:31 | Insight

Kai Rejeski: Underestimated aspect of CAR T-cell therapy: non-relapse mortality

Kai Rejeski, Visiting investigator at Memorial Sloan Kettering Cancer Center, shared on X: “Hot off…

All: 3 Posts: 1 - 100

'

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

'

Highlights from ELCC 2025

'

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023